Cystatin C Levels, Status of Oxidant-Antioxidant and Inflammation in Hemodialysis Patients

Abstract

Objective: Cystatin C is considered an important marker for the detection of renal dysfunction. It was aimed to determine cystatin C levels, status of oxidant-antioxidant and inflammation in hemodialysis (HD) patients. Methods: The study groups consisted of 20 HD patients and 20 healthy controls. Blood samples were obtained from the control group and from the HD group before hemodialysis. Serum cystatin C, total antioxidant capacity (TAC), total oxidative state (TOS), tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) interleukin 18 (IL-18) levels were detected by Enzyme Linked Immunosorbent Assay (ELISA), C-reactive protein (CRP) and some biochemical parameters were analyzed by autoanalyser. Results: Cystatin C, TOS, TNF-α, IL-6, IL-18 and CRP levels of the HD group were significantly higher than the control group. Conclusion: As a result; oxidative stress and inflammation were increased in patients with chronic renal failure undergoing hemodialysis. New strategies and new studies are needed to reduce the increase in oxidative stress and inflammation in HD patients.

Keywords

• Hemodialysis patients
• cystatin C
• oxidative stress
• inflammation

Hemodializ Hastalarında Sistatin C Düzeyleri, Oksidan-Antioksidan ve İnflamasyon Durumu

Abstract

Amaç: Sistatin C, böbrek fonksiyon bozukluğunun saptanması için önemli bir belirteç olarak kabul edilir. Hemodiyaliz (HD) hastalarında sistatin C düzeylerinin, oksidan-antioksidan ve inflamasyon durumunun belirlenmesi amaçlandı. Yöntem: Çalışma grupları 20 HD hastası ve 20 sağlıklı kontrolden oluşturuldu. Hemodiyaliz öncesi kontrol grubundan ve HD grubundan kan örnekleri alındı. Serum sistatin C, total antioksidan kapasite (TAC), total oksidatif durum (TOS), tümör nekroz faktör alfa (TNF-α), interlökin 6 (IL-6), interlökin 18 (IL-18) seviyeleri ELISA ile C- reaktif protein (CRP) ve bazı biyokimyasal parametreler ise otoanalizörde analiz edildi. Bulgular: HD grubunun sistatin C, TOS, TNF-α, IL-6, IL-18 ve CRP düzeyleri kontrol grubuna göre anlamlı derecede yüksekti. Sonuç: Sonuç olarak; hemodiyaliz uygulanan kronik böbrek yetmezliği olan hastalarda oksidatif stres ve inflamasyon artmıştır. Hemodiyaliz hastalarında oksidatif stres ve inflamasyonu azaltmak için yeni stratejilere ve yeni çalışmalara ihtiyaç vardır.

Keywords

• hemodiyaliz hastaları
• sistatin C
• oksidatif stres
• inflamasyon

References

1. Acar Agıragaç U. Investigation of the Relationship Between Renal Functions and Cystatin C in Preeclampsia Patients [Master Thesis]. Şanlıurfa, Turkey: Harran University,2014.http://acikerisim.harran.edu.tr:8080/xmlui/bitstream/handle/11513/1494/463948.pdf?sequence=1&isAllowed=y
2. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998;58:585-592. doi:10.1080/00365519850186210.
3. Arslan OA, Ozturk G, Arslan B, Tukek T. The effect of cystatin-C and pro-BNP in determining mortality in elderly patients with sepsis. Gaziantep Med J. 2014;20(1):47-51. doi:10.5455/GMJ-30-45929.
4. Cachofeiro V, Goicochea M, Vinuesa SG, Oubin P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;74(111):4-9. doi:10.1038/ki.2008.516.
5. Liguori I, Russo G, Curcio F, et al. P. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;3:757-772.
6. Acaroz U, Ince S, Arslan-Acaroz D, et al. The ameliorative effects of boron against acrylamide-induced oxidative stress, inflammatory response, and metabolic changes in rats. Food and Chemical Toxicology, 2018; 118: 745-752.
7. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017: 8416763.
8. Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative stress in hemodialysis patients: A review of the literature. Oxid Med Cell Longev. 2017;2017:3081856. doi:10.1155/2017/3081856.

9. Ozkok A. Endothelial Progenitor Cells, Inflammation and Endothelial Dysfunction in Chronic Hemodialysis Patients: Comparison of Nocturnal and Conventional Hemodialysis Modalities [Master Thesis]. Istanbul: Istanbul University, Istanbul Medical School; 2010.
10. Avcı Cicek E. Biochemical Evaluation of Inflammatory Status in Chronic Kidney Failure Patients [Master Thesis]. Denizli: Pamukkale University; 2013.
11. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37:79-83. doi:10.1053/ajkd.2001.20628.
12. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: Efficacy as screening test for reduce glomerular filtration rate. Am J Nephrol. 2000;20:97-102. doi:10.1159/000013564.
13. Bokenkamp A, Ozden N, Dieterich C, Schumann G, Ehrich JH, Brodehl J. Cystatin C and creatinine after successful kidney transplantation in children. Clin Nephrol. 1999;52:371-376. PMID: 10604645.
14. Mitsnefes M, Kimbal T, Kartal J, Kathman T, Mishra J, Devarajan P. Serum cystatin C and left ventricular diastolic dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2006;21:1293-1298. doi:10.1007/s00467-006-0132-4.
15. Montini G, Amici G, Milan S, et al. Italian registry of paediatric peritoneal dialysis. Middle molecule and small protein removal in children on peritoneal dialysis. Kidney Int. 2002;61:1153-1159. doi:10.3747/pdi.2014.00071.
16. Newman DJ, Takkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312-318. doi:10.1038/ki.1995.40.
17. Coll E, Botey A, Álvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34. doi:10.1053/ajkd.2000.8237.
18. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416-1421. doi:10.1111/j.1523-1755.2004.00517.x.
19. Peralta CA, Whooley MA, Ix JH, Shlipak MG. Kidney function and systolic blood pressure. New insights from cystatin C: Data from the Heart and Soul Study. Am J Hypertens. 2006; 19:939-946. doi:10.1016/j.amjhyper.2006.02.007.
20. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Bagnis CI. Is serum cystatin C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426-432. doi:10.1016/j.amjmed.2008.01.040.
21. De Boer IH, Astor BC, Kramer H, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the Multi-Ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008;3:125-132. doi:10.2215/CJN.03390807.
22. Font R, Prats M, Gutiérrez C, et al. Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic kidney disease? Nefrologia. 2009;29(3):228-235. doi: 10.3265/Nefrologia.2009.29.3.5242.en.full.
23. Giardini O, Taccone-Gallucci M, Lubrano R, et al. Evidence of red blood cell membrane lipid peroxidation in haemodialysis patients. Nephron. 1984;36(4):235-237.
24. Eliselt J, Racek J, Trefil L, Opatrny K. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs. 2001;25(6):430-436. doi:10.1046/j.1525-1594.2001.025006430.x.
25. Drai J, Bannier E, Chazot C, et al. Oxidants and antioxidants in long-term haemodialysis patients. Farmaco. 2001;56(5-7):463-465. doi:10.1016/s0014-827x(01)01063-1.
26. Dursun E, Özben T, Süleymanlar G, Dursun B, Yakupoglu G. Effect of hemodialysis on the oxidative stress and antioxidants. Clinical Chemistry Lab Med. 2002;40(10):1009-1013. doi:10.1515/CCLM.2002.175.
27. Buyukbaş S, Inal A, Atalay H. Evaluation of oxidative activity in hemodialysis patients. Journal of Medical Research. 2007;5(3):105-110.
28. Mimic-Oka J, Simic T, Djukanoviç L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin.Nephrol. 1999;51:233-241. PMID: 10230556.
29. Kuroda M , Asaka S , Tofuku Y , Takeda R. Serum antioxidant activity in uremic patients. Nephron. 1985;41(3):293-298. doi:10.1159/000183600.
30. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41(8):1135-1138.
31. Toborek M, Wasik T, Drózdz M, Klin M, Magner-Wróbel K, Kopieczna-Grzebieniak E. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolis. 1992;41(11):1229-1232. doi:10.1016/0026-0495(92)90014-2.
32. Romuk E, Szczurek W, Nowak P, et al. Effects of propofol on oxidative stress parameters in selected parts of the brain in a rat model of parkinson disease. Postepy Hig Med Dosw. 2016;70(0):1441-1450. doi:10.5604/17322693.1227841.
33. Gonenc A. Lipid Peroxidation and Antioxidant Systems in Patients with Chronic Renal Failure. [PhD thesis]. Ankara, Türkiye: Gazi University, 1999.
34. Whitehead TP, Jungner I, Robinson D, Kolar W, Pearl A, Hale A. Serum urate, serum glucose and diabetes. Ann Clin Biochem. 1992;29:159-161. doi:10.1177/000456329202900206.
35. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009-1016. doi:10.1111/j.1523-1755.2004.00465.x.
36. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454: 428-435. doi:10.1038/nature07201. 37. Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(Suppl. 3):iii35-iii40. doi:10.1093/ndt/gfy175.
37. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997;78:273-277. doi:10.1136/hrt.78.3.273.
38. Stompor T, Pasowicz M, Sullowicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis. 2003;41:203-211. doi:10.1053/ajkd.2003.50005.
39. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767-804. doi:10.1146/annurev.iy.11.040193.004003.
40. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79:399-407. doi:10.1159/000045084.
41. Chiang CK, Hsu SP, Pai MF, et al. Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant. 2004;19:2810-2815. doi:10.1159/000126926.
42. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005;16(Suppl. 1):83-88. doi:10.1681/asn.2004110972.
43. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol. 2006;17(Suppl. 3):169-173. doi:10.1681/ASN.2006080910.
44. Wong CK, Szeto CC, Chan MH, et al. Elevation of pro-inflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest. 2007;36:47-57. doi:10.1080/08820130600745505.
45. Yano A, Nakao K, Sarai A, et al. Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. Nephrology (Carlton). 2005;10:576-582. doi:10.1111/j.1440-1797.2005.00497.x.
46. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603. doi:10.1161/hc3901.096721.
47. Woldbaek PR, Sande JB, Stromme TA, et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol. 2005;289: H708-H714. doi:10.1152/ajpheart.01179.2004.
48. Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245-257. doi:10.1084/jem.20011022.
49. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30. doi:10.1161/01.cir.0000020546.30940.92.
50. Liu YW, Su CT, Chang YT, et al. Elevated serum interleukin-18 level is associated with all-cause mortality in stable hemodialysis patients independently of cardiac dysfunction. Plos One. 2014;9(3):e89457. doi:10.1371/journal.pone.0089457.
51. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;10:53-61. doi:10.1159/000014479.
52. Borazan A, Ustun H, Ustundag Y, et al. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm. 2004;13(3):201-204. doi:10.1080/09511920410001713493.